MSD (Merck & Co.)

Biomarkers

• KRAS G12C10
• MSI-H / dMMR7
• BRCA1/2 mutation1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pembrolizumab 13calderasib 10cetuximab 7sacituzumab tirumotecan 4bevacizumab 2durvalumab 1patritumab deruxtecan 1lenvatinib 1olaparib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2027-03 Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Phase 2 · MSI-H / dMMR
• 2027-05 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Phase 3 · EGFR exon 19 deletion / L858R
• 2027-05 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Phase 3 · MSI-H / dMMR
• 2027-05 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Phase 2 · MSI-H / dMMR

Trials

20 of 30 trials shown

1. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

   Recruiting Phase 3 MSD (Merck & Co.) Started 2026Primary completion 2032-12 NCT07554339

   calderasibdurvalumab

   …rvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platin…

   KRAS G12CNon-small Cell Lung Cancer

2. MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

   Recruiting Phase 3 MSD (Merck & Co.) Started 2026Primary completion 2039-10 NCT07431827

   calderasibpembrolizumab

   Tumor tissue shows the presence of Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation

   KRAS G12CNon-small Cell Lung Cancer

3. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

   Recruiting Phase 3 MSD (Merck & Co.) Started 2025Primary completion 2029-03 NCT06997497

   calderasiboxaliplatinleucovorinfluorouracilcetuximabbevacizumab

   Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation

   KRAS G12CColon Adenocarcinoma, Rectal Adenocarcinoma

4. A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

   Recruiting Phase 3 MSD (Merck & Co.) Started 2025Primary completion 2029-12 NCT07190248

   calderasibpembrolizumabpemetrexedcisplatincarboplatin

   …inum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

   KRAS G12CNon-small Cell Lung Cancer

5. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

   Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2024Primary completion 2028-08 NCT06305754

   sacituzumab tirumotecanpemetrexedcarboplatinH1 Receptor AntagonistH2 Receptor AntagonistAcetaminophen (or equivalent)dexamethasone

   …etrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGF…

   EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC)

6. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

   Recruiting Phase 3 MSD (Merck & Co.) Started 2024Primary completion 2028-01 NCT06345729

   calderasibpembrolizumab

   A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum…

   KRAS G12CNon-small Cell Lung Cancer

7. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

   Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2023Primary completion 2027-05 NCT06074588

   sacituzumab tirumotecandocetaxelpemetrexed

   …iously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

   EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC)

8. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

   Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2022Primary completion 2028-09 NCT05239741

   pembrolizumab FDA EUoxaliplatinleucovorinfluorouracilirinotecanbevacizumabcetuximab

   …ersus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)

   MSI-H / dMMRColorectal Neoplasms

9. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

   Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2022Primary completion 2027-05 NCT05173987

   pembrolizumab FDA EUcarboplatinpaclitaxeldocetaxelcisplatin

   …l Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR.

   MSI-H / dMMREndometrial Neoplasms

10. A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

    Recruiting Phase 1/2 MSD (Merck & Co.) Started 2026Primary completion 2029-08 NCT07286149

    calderasibpatritumab deruxtecansacituzumab tirumotecancetuximabRescue Medications

    …of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations

    KRAS G12CKRAS G12DLung Neoplasm Malignant

11. A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

    Recruiting Phase 1/2 MSD (Merck & Co.) Started 2026Primary completion 2029-03 NCT07302347

    pembrolizumab FDA EU

    For participants with microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) solid tumors:

    MSI-H / dMMRMalignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma

12. KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

    Recruiting Phase 2 MSD (Merck & Co.) Started 2025Primary completion 2029-11 NCT07252739

    calderasibpembrolizumabcetuximabsacituzumab tirumotecanRescue medication

    …cid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations

    KRAS G12CMalignant Neoplasm

13. A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

    Recruiting Phase 2 MSD (Merck & Co.) Started 2025Primary completion 2032-04 NCT07209111

    calderasibcetuximab

    Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation

    KRAS G12CNeoplasm Malignant

14. Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2021Primary completion 2027-03 NCT04976634

    pembrolizumab FDA EUBelzutifanlenvatinib

    Colorectal cancer (CRC) (non-microsatellite instability-high \[non-MSI-H\]/deficient mismatch repair \[dMMR\])

    MSI-H / dMMRNeoplasm Malignant

15. Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2021Primary completion 2025-05 NCT04895722

    pembrolizumab FDA EUMK-4830

    Has locally confirmed dMMR/MSI-H

    MSI-H / dMMRColorectal Cancer

16. Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2018Primary completion 2025-08 NCT03742895

    olaparib FDA EU

    For participants who have somatic BRCAm breast cancer:

    BRCA1/2 mutationAdvanced Solid Neoplasms

17. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2015Primary completion 2027-05 NCT02628067

    pembrolizumab FDA EU

    …r, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR

    MSI-H / dMMRAdvanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer

18. A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

    Recruiting Phase 1 MSD (Merck & Co.) Started 2025Primary completion 2030-12 NCT07247110

    MK-4716pembrolizumabcetuximab

    …716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration

    KRAS G12CKRAS G12DMalignant Neoplasm

19. Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

    Active, not recruiting Phase 1 MSD (Merck & Co.) Started 2023Primary completion 2028-06 NCT05853367

    MK-0472pembrolizumabcalderasib

    …histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation

    KRAS G12CMSI-H / dMMRMetastatic Solid Tumors, Advanced Solid Tumors

20. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

    Recruiting Phase 1 MSD (Merck & Co.) Started 2021Primary completion 2030-02 NCT05067283

    calderasibpembrolizumabcarboplatinpemetrexedcetuximaboxaliplatinleucovorinfluorouracil

    …e or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease

    KRAS G12CKRAS G12DAdvanced Solid Tumors

No trials match these filters.